# Suvorexant to Reduce Symptoms of Nicotine Use

> **NCT04234997** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 14 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** Suvorexant 20 mg
- **DRUG:** Suvorexant 0mg

## Key facts

- **NCT ID:** NCT04234997
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-23
- **Primary completion:** 2024-08-22
- **Final completion:** 2024-08-22
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04234997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04234997, "Suvorexant to Reduce Symptoms of Nicotine Use". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04234997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*